• Publications
  • Influence
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
The calcineurin inhibitors cyclosporine (INN, ciclosporin) and tacrolimus have a narrow therapeutic index and show considerable interindividual variability in their pharmacokinetics. The low oralExpand
Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation.
TLDR
The goal of this consensus meeting was to offer information to transplant practitioners on clinically relevant pharmacokinetic characteristics of MPA, to rationalize the basis for currently advised target exposure ranges for MPA in various types of organ transplantation, and to summarize available methods for application of M PA TDM in clinical practice. Expand
A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney
TLDR
MPA C predose and MPA AUC are significantly related to the incidence of biopsy-proven rejection after kidney transplantation, whereas MMF dose is significantly relatedto the occurrence of adverse events. Expand
UGT1A9 −275T>A/−2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus‐Treated Kidney Transplant Patients
TLDR
UGT1A9 −275T>A and/or −2152C>T genotyping may identify patients at risk of MPA underexposure and acute rejection when receiving treatment with MMF and tacrolimus. Expand
The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
TLDR
The risk of breast cancer mortality is increased in tamoxifen users with decreased CYP2D6 activity, consistent with the model in which endoxifens formation is dependent on CYP 2D6 action. Expand
Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Recipients
TLDR
A population pharmacokinetic model for MPA following oral administration of mycophenolate mofetil is developed and identified correlations appear to explain part of the observed inter- and intrapatient pharmacokinetics variability. Expand
Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR‐1, CYP3A4, and CYP3A5 genes
Our objective was to determine the relationship between single nucleotide polymorphisms (SNPs) in the multidrug resistance 1 (MDR‐1) gene and the cytochrome P450 (CYP) genes CYP3A4 and CYP3A5 and theExpand
Limited Sampling Strategies for Therapeutic Drug Monitoring of Mycophenolate Mofetil Therapy in Patients With Autoimmune Disease
TLDR
MAP-BEs were developed for the estimation of MPA AUC0-12 in patients with AID using a limited number of samples and the predictive performance was good and comparable to those of the multiple linear regression method. Expand
Research Paper: Turning Off Frequently Overridden Drug Alerts: Limited Opportunities for Doing It Safely
TLDR
Turning off DDI alerts hospital-wide appeared to be problematic because of differences among physicians regarding drug-related knowledge and of differences across the hospital in routine drug monitoring practices. Expand
Genetic Variation in the CYP2D6 Gene Is Associated With a Lower Heart Rate and Blood Pressure in β‐Blocker Users
TLDR
The association between CYP2D6*4 and blood pressure or heart rate was examined in 1,533 users of β‐blockers in the Rotterdam Study, a population‐based cohort study and found PMs are at increased risk of bradycardia. Expand
...
1
2
3
4
5
...